* To replay the media content and watch again, please refresh your screen

Follow a patient's journey through advanced HCC and make decisions on treatment selection and sequencing in this interactive patient case video presented by Prof. Dr Timon Vandamme.

 

As you interact and engage with valuable information, challenging questions, and clickable resources, you'll choose your preferred 1st line treatment option for this patient, when to switch to 2nd line treatment, and which 2nd line option to recommend.

 

Clinical Takeaways

  • IO based treatments are the first choice for patients with advanced HCC without active auto-immune disease and without liver transplant
  • In case of slow progression, continuing IO based treatment should be considered for patients with HCC
  • Research is ongoing to determine the best treatment options and sequencing after progression on IO based treatment for patients with HCC

Educational Objectives

  • Understand the systemic treatment options for patients with advanced and intermediate HCC
  • Know the treatment options for patients with advanced HCC not eligible for immunotherapy in 1st line
  • Know the right time to switch to 2nd line therapy (including progression and patient evaluation, such as liver function) and implement optimal sequencing

Timon Vandamme is a Senior Consultant in digestive and neuroendocrine oncology at the Antwerp University Hospital. As a clinician-researcher, he is performing research in circulating cell-free DNA (ccfDNA) in digestive and neuroendocrine neoplasms.

 

Dr Vandamme obtained a joint PhD at the University of Antwerp, Belgium and the Erasmus MC, the Netherlands, on preclinical and translation evaluation of everolimus resistance and pancreatic NET genomics. His PhD project has led to multiple publications in peer-reviewed journals and received numerous awards, both national and international. Currently, he is holder of a Senior Clinical Investigator (FKM) grant of the Fonds Wetenschappelijk Onderzoek (FWO) at the University of Antwerp.

 

Furthermore, he is the Principal Investigator (PI) of > 10 trials at the University Hospital Antwerp, both industry-sponsored and academic trials. He is promotor of four PhD students and mentor of two additional PhD students. He has authored numerous papers outside his PhD in journals such as Clinical Cancer Research and Lancet Oncology. He has peer-reviewed for different high-impact journals and is a member of the editorial board of Endocrine-Related Cancer.

He is currently acting secretary of the Dutch Belgian Neuroendocrine Tumor Society (DBNETS) and co-opted board member of the Belgian Group of Digestive Oncology (BGDO). In addition, he is active member of the EORTC GI Tract Cancer Group and the ENETS Translational Working Group.

 

Programme summary
  • clock Duration 15 MIN
  • clock Language(s) flag
Other episodes of this series
Advanced HCC: When to switch to 2nd line treatment

Advanced HCC: When to switch to 2nd line treatment

Explore treatment selection and optimal sequencing after progression on immunotherapy in an interactive patient case video

Current Episode
Advanced HCC: Treatment options for patients ineligible for IO

Advanced HCC: Treatment options for patients ineligible for IO

Explore treatment options, adverse event management and next steps in this interactive patient case

Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast
Oncology 
HR+/HER2- metastatic breast cancer: Best practices in molecular testing and targeted therapy

Optimising precision medicine for improved patient outcomes

Experts
Dr Roberto Salgado, Assoc. Clinical Professor Rena Callahan
Endorsed by
ICAN international cancer advocacy network ISLB Exon20group
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2025

Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.
conference-update Conference update
Oncology 
Current and future treatment strategies for patients with ER+/HER2- early breast cancer

A closer look at the evolving treatment landscape

Experts
Prof. Michael Gnant, Prof. Giuseppe Curigliano
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Mar 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast
Oncology 
ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses

Experts' insights on treatment strategies in ER+ metastatic breast cancer settings

Experts
Dr Aditya Bardia, Dr Virginia Kaklamani
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
LEAP-012 publication snapshot

Expert insights on multimodal treatment for intermediate hepatocellular carcinoma (HCC)

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery plus
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
eks
Experts Knowledge Share Video
Oncology 
HER2 testing: The evolving role of immunohistochemistry (IHC)

Best practices and interpretation of results in lung and ovarian cancer 

Experts
Prof. Fernando López-Ríos, MD, PhD, Prof. Christian Rolfo, Prof. Charlie Gourley
Endorsed by
Exon20group ICAN international cancer advocacy network Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 77 MIN
  • calendar Mar 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
conference-update Conference update
Oncology 
ER+ metastatic breast cancer: Highlights from the 13th APBCS Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer  

Experts
Prof. Shaheenah Dawood, Prof. Heather McArthur, Prof. Javier Cortés, Prof. Frédérique Penault-Llorca
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.